<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875875</url>
  </required_header>
  <id_info>
    <org_study_id>Ericsson-001</org_study_id>
    <nct_id>NCT00875875</nct_id>
  </id_info>
  <brief_title>Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea</brief_title>
  <acronym>Rifaximin 600</acronym>
  <official_title>Single Daily Dose Rifaximin vs. Standard Thrice Daily Dosing for the 3-Day Treatment of Travelers' Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare durations of diarrhea among subjects who report to clinic for
      treatment and who receive either:

        1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR

        2. a single 600 mg dose of rifaximin daily for 3 days.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No study population in Mexico (H1N1). Study withdrawn from IRB consideration.
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from beginning therapy to passage of last unformed stool</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects as reported by the subjects on diaries</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Travelers' Diarrhea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the approved treatment regimen for travelers' diarrhea (600 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the same dose as the standard dose, given once daily (200 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Xifaxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  passage of 3 or more unformed stools in 24 hours plus an additional symptom of enteric
             disease such as abdominal cramps, nausea, vomiting, or fever; and investigator
             verification that an unformed stool has been submitted.

          -  is &gt; 18 years of age

          -  has diarrhea (at least three unformed stools in 24 hrs) plus at least one additional
             sign or symptom of enteric illness

          -  has acute diarrhea less than 1 week's duration

          -  willingness to provide a diarrhea stool sample

          -  willingness to keep a daily diary for 5 days

          -  signed informed consent

        Exclusion Criteria:

          -  fever or bloody diarrhea

          -  has taken predictably effective antibiotics in the past week (e.g. quinolones,
             TMP/SMX, azalide or doxycycline)

          -  is pregnant now, likely to become pregnant, or breast-feeding

          -  has duration of diarrhea of greater than 1 weeks

          -  is allergic to Rifampin or Rifaximin

          -  has a history of significant underlying enteric, pulmonary, cardiac, renal disease, or
             any CNS disorder

          -  is more than moderately dehydrated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles D Ericsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Medical School at Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Enteric Disease Clinic</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2009</study_first_posted>
  <last_update_submitted>June 8, 2015</last_update_submitted>
  <last_update_submitted_qc>June 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Charles D Ericsson</investigator_full_name>
    <investigator_title>â—¦Professor and Dr. and Mrs. Carl V. Vartian Professor in Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Diarrhea, travelers</keyword>
  <keyword>Acute travelers' diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Dysentery</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

